Medtronic

Loading

2014 Press Releases


2014 | 2013 | 2012 | 2011 | 2010 | 2009
Search News Releases
 
DateTitle  
10/20/14Medtronic Announces Global Launch of Titanium-Coated Peek Interbody Fusion Devices
MEMPHIS, TENN., - October 20, 2014 - Medtronic, Inc. (NYSE: MDT) introduced its Pure Titanium Coating (PTC) platform of interbody fusion devices for the spine today at the 2014 Congress of Neurological Surgeons (CNS) Annual Meeting in Boston. The PTC platform includes four products: the CAPSTONE PTC(TM) Spinal System, CLYDESDALE PTC(TM) Spinal System, ANATOMIC PEEK PTC Cervical Fusion System and CORNERSTONE-SR® Ti- Coated Anatomical Cervical Cage. These devices are used to treat patients exper... 
Download PDFPrinter Friendly Version
10/14/14Medtronic Announces FDA Approval of Pacing Lead for Full-Body MRI Scans
CapSureFix Novus(TM) MRI SureScan ® 5076 Pacing Lead Approved for MR-Conditional Use in Patients with Slow Heartbeat MINNEAPOLIS - October 14, 2014 -- Medtronic today announced the U.S. Food and Drug Administration (FDA) approval of its CapSureFix Novus(TM) MRI SureScan® 5076 Lead for use with magnetic resonance imaging (MRI). The lead is approved for MRI scans positioned on any region of the body when paired with a Medtronic dual-chamber MR-conditional pacemaker. The 5076 lead, previously appro... 
Download PDFPrinter Friendly Version
10/14/14Medtronic Begins Pivotal Study of First Predictive Low Glucose Management Technology for People with Diabetes
In-Clinic Study Marks Critical Step Toward an Artificial Pancreas and Key Milestone Toward U.S. Commercialization MINNEAPOLIS - October 14, 2014 - Medtronic, Inc. (NYSE:MDT) today announced that the first patients have been enrolled in an investigational device exemption (IDE) study of its breakthrough Predictive Low Glucose Management (PLGM) technology, marking a critical step toward development of an artificial pancreas in the U.S. market. The trial will evaluate the safety of its next-genera... 
Download PDFPrinter Friendly Version
10/13/14Medtronic CoreValve System Shows Exceptional Outcomes and Valve Performance in TAVI Patients Treated Via Direct Aortic Access
Late-Breaking ADVANCE Direct Aortic Study Presented at EACTS Reaffirms CoreValve System's Positive Performance with Low Mortality and Stroke MINNEAPOLIS and MILAN - Oct. 13, 2014 -Medtronic, Inc. (NYSE: MDT) today announced positive data from nine European centers in a study of the direct aortic approach (through the upper chest) with the CoreValve® System is a safe and effective alternative for aortic stenosis patients at increased risk for surgery who are not suitable for transcatheter aortic... 
 Printer Friendly Version
10/10/14Medtronic Announces Executive Leadership Team for Combined Organization Upon Close of Covidien Acquisition
MINNEAPOLIS -- October 10, 2014 -- Medtronic (NYSE: MDT) today announced the executive team who will lead the combined organization following the close of its proposed acquisition of Covidien.  The new company will be comprised of four major business groups and four geographic regions led by a new Executive Committee.  Omar Ishrak will remain as chairman and chief executive officer of the new company, Medtronic plc.  "The planned acquisition of Covidien will greatly accelerate our joint v... 
Download PDFPrinter Friendly Version
10/07/14New Evaluation System Leads to Incontinence Relief
FDA-Approved System Provides Patients with Added Benefits While Testing Innovative Therapy for Bladder and Bowel Incontinence MINNEAPOLIS - October 7, 2014 - After living with overactive bladder and urinary retention symptoms for 11 years, Jennifer LaForest, a 26-year-old woman from Auburn Hills, Michigan, recently became one of the first in the U.S. to receive a test evaluation with the new Verify(TM) Evaluation System from Medtronic, and subsequently received Medtronic Bladder Control Therap... 
Download PDFPrinter Friendly Version
10/03/14Medtronic Announces Updated Financing Plans for Covidien Acquisition
Company reaffirms commitment to Covidien transactionCompany intends to utilize $16 billion in external debt to finance cash portion of transactionTransaction remains strategically and financially compellingDefinitive agreement terms remain unchanged MINNEAPOLIS -October 3, 2014- Medtronic, Inc. (NYSE: MDT), a global leader in medical technology, services and solutions, today announced that it intends to use approximately $16 billion in external financing to complete the acquisition of Co... 
Download PDFPrinter Friendly Version
09/29/14Medtronic Extends Title Sponsorship of Twin Cities Marathon Through 2020
Building on Nearly a Decade of Growth, Partnership Allows Twin Cities In Motion to Continue to Expand and Enhance Race Events and Youth Programming MINNEAPOLIS - Sept. 29, 2014 -Medtronic and Twin Cities In Motion, the organizers of the Medtronic Twin Cities Marathon, today announced a five-year, $2.5 million agreement that will keep Medtronic as the title sponsor of the Twin Cities Marathon and three additional Twin Cities In Motion events through 2020: the TC 1 Mile, TC Family Events, and TC ... 
Download PDFPrinter Friendly Version
09/25/14Medtronic Announces $6 Million Philanthropic Effort to Prevent and Control Rheumatic Heart Disease
$6 Million Marks the Largest Private-Sector Contribution to Date to Address One of the World's Most Neglected, Yet Preventable, Diseases Affecting the World's Poor MINNEAPOLIS - September 25, 2014 - Medtronic today announced a five-year, $6 million (USD) funding commitment from Medtronic Philanthropy to reduce premature mortality resulting from Rheumatic Fever (RF) and Rheumatic Heart Disease (RHD). Funding will support projects focused in three countries yet to be determined.  The commitment... 
Download PDFPrinter Friendly Version
09/22/14Medtronic Announces CE Mark and European Launch of TYRX(TM) Absorbable Antibacterial Envelope
MINNEAPOLIS - Sept. 22, 2014 - Medtronic, Inc. (NYSE: MDT) has received CE (Conformité Européenne) Mark for the TYRX(TM) Absorbable Antibacterial Envelope. This innovative mesh envelope covers an implantable cardiac device to help stabilize the device after implantation and reduce surgical-site infections. The efficacy of the previous generation, non-absorbable TYRX(TM) Antibacterial Envelope* has been shown in three published studies, with new six-month follow-up data from the CITADEL/CENTURI... 
Download PDFPrinter Friendly Version
09/17/14Medtronic Elects Elizabeth Nabel to the Board of Directors
MINNEAPOLIS - Sept. 17, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that its Board of Directors elected Elizabeth Nabel, M.D., president of Brigham & Women's Hospital and Brigham & Women's Faulkner Hospital, to the Board as an independent director. Dr. Nabel is a cardiologist and distinguished biomedical researcher and has served as president of Brigham & Women’s hospital since 2010 where she has led the development of an innovative, comprehensive strategic plan that defines ... 
Download PDFPrinter Friendly Version
09/17/14Medtronic Launches New Balloon Kyphoplasty Products for Treating Spinal Fractures
Enhancements Give Physicians More Options for Treating Vertebral Compression Fractures MEMPHIS, TN - September 17, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the launch of the KYPHON Express(TM) II Balloon Kyphoplasty Platform, which includes the next generation KYPHON ® Cement Delivery System. This new platform is the latest advancement in the KYPHON® Balloon Kyphoplasty (BKP) technology for the treatment of vertebral compression fractures. The KYPHON Express(TM) II Balloon Kyphoplasty... 
Download PDFPrinter Friendly Version
09/16/14Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease
IN.PACT Global Study Reports Favorable Outcomes in Real-World Patient Population and Validates Key Findings from IN.PACT SFA Trial WASHINGTON -- Sept. 16, 2014 -- Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon (DCB) from Medtronic, Inc. (NYSE: MDT) augments an already robust body of evidence that continues to drive a reconsideration of the standard of care for p... 
Download PDFPrinter Friendly Version
09/16/14People with Type 2 Diabetes Achieve Greater Satisfaction with Insulin Pumps vs. Multiple Daily Injections
New Data from the OpT2mise Efficacy Studyto be Presented at EASD Annual Meeting VIENNA - September 16, 2014 - Medtronic, Inc. (NYSE:MDT) today announced that new results from the OpT2mise trial are being presented at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting.  OpT2mise is the largest global study to compare insulin pump therapy to multiple daily insulin injections in people with type 2 diabetes with poor glycemic control. Three new poster presentations at EAS... 
 Printer Friendly Version
09/15/14Medtronic Launches SEEQ(TM) Wearable Cardiac Monitoring System in United States
New External Heart Monitor and Remote Monitoring Center Help Patients Find Answers to Unexplained Cardiac Symptoms MINNEAPOLIS - September 15, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. launch of the SEEQ(TM) Mobile Cardiac Telemetry (MCT) System, an external, wire-free, adhesive heart monitor that can be worn for up to 30 days to help detect and diagnose the cause of irregular heartbeats in patients. Medtronic completed the acquisition of U.S.-based Corventis, Inc., which deve... 
Download PDFPrinter Friendly Version
09/13/14Medtronic CoreValve System Sustains Positive Outcomes Through Two Years in Extreme Risk Patients
TCT Late-Breaking First Report Reveals High Survival, Low Stroke Rates and Sustained Valve Performance WASHINGTON, D.C. and MINNEAPOLIS - Sept. 13, 2014 - Medtronic, Inc. (NYSE: MDT) today announced new data showing that transcatheter aortic valve replacement (TAVR) with the CoreValve® System continued to provide safe and effective treatment, while maintaining exceptional rates of survival out to two years for patients who were considered too ill or frail to have their aortic valves replaced t... 
Download PDFPrinter Friendly Version
09/13/14Medtronic CoreValve Data Demonstrate Favorable Cost Effectiveness Compared to Open-Heart Surgery in High Risk Patients
Cost Effectiveness of Self-Expanding Valve Driven by Improved Quality of Life Benefit and Superior One-Year Survival Rates over Surgical Aortic Valve Replacement WASHINGTON, D.C., and MINNEAPOLIS - Sept. 13, 2014 - In the first-ever in-trial cost effectiveness analysis of transcatheter aortic valve replacement (TAVR) for patients at high risk for surgery, investigators today revealed new data demonstrating the cost effectiveness of the CoreValve® System from Medtronic, Inc. (NYSE: MDT) for h... 
Download PDFPrinter Friendly Version
09/11/14Medtronic Named One of the World's Leading Companies for Sustainability
MINNEAPOLIS - Sept. 11, 2014 - Medtronic, Inc. (NYSE: MDT) was recognized as one of the world's leading companies for sustainability with its ranking on the Dow Jones Sustainability World Index (DJSI World) for the fourth year in a row.  DJSI World analyzes companies on a variety of sustainability criteria, including economic performance, environmental stewardship and social responsibility. This adds to the recognition Medtronic received earlier this year through its continued inclusion in the F... 
Download PDFPrinter Friendly Version
09/11/14Medtronic NC Euphora(TM) Coronary Balloon Receives FDA Clearance
Superior Deliverabilityi and Uncompromising Performance Distinguishes New Angioplasty Balloon New "Cath Lab Connect" Website Will Provide Catheter Lab Professionals with Educational Resources and Best Practice Sharing Platform MINNEAPOLIS -- Sept. 11, 2014 -- Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the NC Euphora(TM) Noncompliant Balloon Dilatation Catheter. The new device will be featured for the first t... 
Download PDFPrinter Friendly Version
09/10/14Medtronic Announces First U.S. Implants in Clinical Study of Recapturable CoreValve Evolut R
First Patients Successfully Treated in Study to Evaluate Next Generation Transcatheter Valve MINNEAPOLIS - Sept. 10, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the first U.S. implants in the CoreValve Evolut R Clinical Study, which will evaluate  the safety and effectiveness of the new Medtronic CoreValve®Evolut(TM) R System. This novel investigational self-expanding valve and 14FR equivalent delivery system offer new capabilities that are designed to advance deliverability and valve p... 
Download PDFPrinter Friendly Version
09/03/14Medtronic Announces CE Mark for Recapturable CoreValve Evolut R System
Next-Generation TAVI System Offers Ability to Recapture and Reposition During Deployment MINNEAPOLIS - Sept. 3, 2014 - Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européene) Mark for the 23 mm CoreValve® Evolut(TM) R System for transcatheter aortic valve implantation (TAVI). The novel, self-expanding valve and 14FR equivalent delivery system offers new capabilities that  advance valve performance and deliverability during the procedure, while providing the option to recapture (r... 
Download PDFPrinter Friendly Version
09/02/14Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference
MINNEAPOLIS - Sept 2, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Morgan Stanley Global Healthcare Conference, September 8, 2014, in New York. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 3:25 p.m. EDT (2:25 p.m. CDT). A live audio webcast of the presentation will be available on September 8, 2014, by clicking on the Invest... 
Download PDFPrinter Friendly Version
08/28/14Medtronic Receives Clearance for the SHILLA(TM) Growth Guidance System
First U.S. Growth Guidance System Cleared to Treat Scoliosis with Children's Needs in Mind MEMPHIS, TN - Aug. 28, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the 510(k) clearance and launch of the SHILLA(TM) Growth Guidance System. The system is designed for treatment of skeletally immature pediatric patients less than 10 years of age diagnosed with severe, progressive, life-threatening, early-onset spinal deformities. The SHILLA(TM) Growth Guidance System is a new growth-sparing tech... 
Download PDFPrinter Friendly Version
08/27/14Medtronic Announces First Implants in Largest-Ever, Global Trial of Cardiac Resynchronization Therapy
Post-Market Clinical Trial Will Assess Superiority of the AdaptivCRT® Feature Compared to Standard CRT MINNEAPOLIS - Aug. 27, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the first implants in a clinical trial that will compare patient and healthcare system outcomes - including patient mortality and hospitalizations - in heart failure patients who have cardiac resynchronization therapy (CRT) devices with the AdaptivCRT® feature enabled versus patients receiving standard CRT. The AdaptRespo... 
Download PDFPrinter Friendly Version
08/27/14Medtronic Acquires NGC Medical to Strengthen Its Integrated Health Solutions Portfolio
NGC's Hospital Managed Services Business Adds to Medtronic's Growing Healthcare Services and Solutions Portfolio TOLOCHENAZ - August 27, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has completed the acquisition of NGC Medical S.p.A. (NGC), a privately-held Italian company, in a transaction that values NGC at $350 million. Medtronic held a 30 percent ownership stake in the company prior to the completion of the acquisition. NGC will serve as the Managed Services arm for Medtronic'... 
Download PDFPrinter Friendly Version
08/26/14Medtronic Acquires Sapiens Steering Brain Stimulation
Sapiens' Deep Brain Stimulation Technologies Strengthen Medtronic's Neuromodulation Portfolio and Neuroscience Leadership Position MINNEAPOLIS and EINDHOVEN - Aug. 26, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has acquired Sapiens Steering Brain Stimulation (Sapiens SBS), a privately held developer of deep brain stimulation (DBS) technologies for approximately $200 million in an all-cash transaction. The acquisition of Sapiens SBS strengthens Medtronic's capabilities in an impor... 
Download PDFPrinter Friendly Version
08/25/14Medtronic Viva® Cardiac Resynchronization Therapy-Pacemaker Now Available in U.S.
AdaptivCRT® Algorithm Customizes Therapy for Heart Failure Patients and Improves Their Response Rates MINNEAPOLIS - Aug. 25, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P, for indicated patients with heart failure or atrioventricular (AV) block. The Viva CRT-P includes the Medtronic-exclusive AdaptivCRT® algorithm, which preserves normal heart rhythms and automatically ... 
Download PDFPrinter Friendly Version
08/21/14Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2015
MINNEAPOLIS - August 21, 2014 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.305 per share of the company's common stock. The quarterly dividend represents a 9 percent increase over the prior year. The dividend is payable on October 24, 2014, to shareholders of record at the close of business on October 3, 2014. Medtronic, a constituent of the S&P 500 Dividend Aristocrats index, has committed to returning 50 percent of its free cash flow to shareholde... 
Download PDFPrinter Friendly Version
08/20/14Greater Twin Cities United Way and Medtronic Join Forces to Advance Health Equity in Minnesota
MINNEAPOLIS - August 20, 2014 - Greater Twin Cities United Way today strengthened their long-standing commitment to improving the health and well-being of Twin Cities' communities by teaming up with Medtronic Philanthropy on a new partnership designed to promote access to quality healthcare in the region. This commitment is a five-year, $2.5-million initiative that will leverage shared research, resources and community-based approaches to give people in underserved communities a better chance to... 
Download PDFPrinter Friendly Version
08/19/14Medtronic Reports First Quarter Earnings
Revenue of $4.3 Billion Grew 4% on Constant Currency Basis; 5% as Reported Non-GAAP Diluted EPS of $0.93, Growth of 6%; GAAP Diluted EPS of $0.87, Decline of 6% Company Reiterates FY15 Revenue Growth Outlook and EPS Guidance Company Reaffirms Commitment to Covidien Transaction MINNEAPOLIS - Aug. 19, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2015, which ended July 25, 2014. The company reported worldwide first quarter revenu... 
Download PDFPrinter Friendly Version
08/11/14Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2015
MINNEAPOLIS - Aug. 11, 2014 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the first quarter of its fiscal year 2015 on Tuesday, August 19, 2014. A news release will be issued at approximately 6:15 a.m. Central Daylight Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic's first fiscal quarter which ended July 25, 2014. Medtronic will host a webcast at 7:00 a.m. Centra... 
Download PDFPrinter Friendly Version
08/11/14Medtronic Announces 2014 "Global Heroes" Team
Distance Runners from Around the World Who Benefit from Medical Technology to Run Medtronic Twin Cities Marathon Events this Fall MINNEAPOLIS - August 11, 2014 - Twenty-five long-distance runners who benefit from medical technology will be honored as "Medtronic Global Heroes" when they run as a team in the Medtronic Twin Cities Marathon or TC 10 Mile on Sunday, October 5, 2014. This year's team includes runners from 10 different countries: Australia, Brazil, Canada, China, Colombia... 
Download PDFPrinter Friendly Version
08/07/14Medtronic Receives FDA Approval for Attain Performa® Quadripolar Lead and Viva® Quad CRT-Ds in United States
New System Helps Physicians Deliver Cardiac Resynchronization Therapy Optimally and Efficiently to Heart Failure Patients MINNEAPOLIS - Aug. 7, 2014 - Medtronic, Inc. (NYSE: MDT) today announced it has received United States Food and Drug Administration (FDA) approval for the Attain Performa® Model 4298 quadripolar lead, and the Viva® Quad XT and Viva® Quad S cardiac resynchronization therapy defibrillators (CRT-D). The quadripolar lead and devices will be broadly available to physicians in mi... 
Download PDFPrinter Friendly Version
08/01/14Medtronic Launches NuVent(TM) EM Sinus Dilation System for Fusion® ENT Navigation System
System Offers Innovative Technology for Sinus Surgery. Chronic Sinusitis Affects Nearly 29 Million US Adults MINNEAPOLIS - August 1, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the launch of the NuVent(TM) EM Sinus Dilation System for the Fusion® ENT Navigation System, developed and manufactured by the company's Ear Nose and Throat (ENT) division of its Surgical Technologies business. NuVent is the first and only balloon sinus dilation system with built-in electromagnetic (EM) surgical n... 
Download PDFPrinter Friendly Version
07/28/14Medtronic Receives FDA Approval for PRESTIGE® LP Cervical Disc System
The PRESTIGE® LP Cervical Disc is Medtronic's Third Clinically-Proven Artificial Cervical Disc to Receive FDA Approval MEMPHIS, TENN. - July 28, 2014 - Medtronic, Inc. (NYSE: MDT) announces that it has received approval from the U.S. Food and Drug Administration (FDA) to market the PRESTIGE® LP Cervical Disc System for the treatment of single-level cervical disc disease (radiculopathy and/or myelopathy). The PRESTIGE® LP Cervical Disc is the third clinically proven artificial cervical disc in... 
Download PDFPrinter Friendly Version
07/28/14Medtronic Completes Acquisition of Visualase, Inc.
MRI-Guided Laser Ablation Technology Adds to Surgical Technologies Product Portfolio and Broader Neuroscience Leadership Position MINNEAPOLIS - July 28, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has completed the acquisition of Visualase, Inc., a privately held company based in Houston, TX, that develops and markets an FDA-approved MRI-guided laser and image guided system for minimally invasive neurosurgeries, including surgical thermal ablation.  Medtronic will add Visualase'... 
Download PDFPrinter Friendly Version
07/02/14People with Type 2 Diabetes Achieve Superior Outcomes with Insulin Pumps vs. Multiple Daily Injections
Comparative Efficacy Results from the OpT2mise Trial Published in The Lancet Could Redefine Management of Insulin-Requiring Type 2 Diabetes MINNEAPOLIS - July 2, 2014 - As an example of its commitment to improving clinical outcomes for all people with diabetes, Medtronic, Inc. (NYSE:MDT) today announced the results of the OpT2mise trial, which showed that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections... 
 Printer Friendly Version
06/25/14Study Published in The New England Journal of Medicine Finds Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation in Stroke Patients Better Than Standard Care
MINNEAPOLIS - June 25, 2014 - Medtronic, Inc. (NYSE: MDT), today announced results from the CRYSTAL AF (CRYptogenic STroke And underLying Atrial Fibrillation) Clinical Trial have been published in The New England Journal of Medicine. The Trial found that continuous cardiac monitoring with the Reveal® XT Insertable Cardiac Monitor (ICM) was superior to standard care at detecting atrial fibrillation (AF) in patients who have had strokes of undetermined causes (cryptogenic stroke). The global study... 
Download PDFPrinter Friendly Version
06/19/14Medtronic Announces Preliminary Outcomes for World's Smallest Cardiac Pacemaker
Results Presented at Cardiostim 2014 MINNEAPOLIS and NICE, France - June 19, 2014 - Medtronic, Inc. (NYSE: MDT) today announced preliminary results from the first human implants of the world's smallest pacemaker, the Micra(TM) Transcatheter Pacing System (TPS). Results from the first four patients to receive the Micra TPS were reported at CARDIOSTIM / EHRA EUROPACE 2014, World Congress in Electrophysiology and Cardiac Techniques, in Nice, France. At 1 month and 3 months, results showed the Mic... 
Download PDFPrinter Friendly Version
06/18/14Study Shows CRT-D Devices with Medtronic AdaptivCRT(TM) Associated with Reduction of Costs of Atrial Fibrillation
Study Supplements Earlier Data Showing Reduction in Hospital Readmissions for Heart Failure Patients with AdaptivCRT Technology MINNEAPOLIS, USA and NICE, FRANCE - June 18, 2014 - New data from the Medtronic, Inc. (NYSE: MDT) Adaptive CRT trial show a 61 percent (p=0.01) lower risk of atrial fibrillation (AF)-related problems in patients who receive a cardiac resynchronization therapy-defibrillator (CRT-D) with the Medtronic-exclusive AdaptivCRT(TM) algorithm compared to conventional biventricu... 
Download PDFPrinter Friendly Version
06/17/14Medtronic Launches $17-Million Program to Improve Heart Disease, Diabetes Care for Underserved Populations
HealthRise Program Supports Localized Healthcare Access Projects in Four Countries as Part of Global Effort to Lessen the Burden of Chronic, Non-Communicable Diseases (NCDs)  MINNEAPOLIS - June 17, 2014 - Medtronic today announced the launch of HealthRise, a five-year, $17-million (USD) Medtronic Philanthropy program that supports community-based demonstration projects specifically designed to expand access to care and management of chronic, non-communicable diseases (NCDs) such as heart disease... 
Download PDFPrinter Friendly Version
06/16/14Medtronic Increases Its Cash Dividend By Nine Percent
Commitment Remains to Return 50 Percent of Free Cash Flow to Shareholders MINNEAPOLIS - June 16, 2014 - The board of directors of Medtronic, Inc. (NYSE: MDT) approved yesterday a 9 percent increase in its cash dividend, raising the quarterly amount to $0.305 per share of the company's common stock, which would result in an annual amount of $1.22 per share.  This dividend increase brings the company's current dividend yield to 2 percent and expected fiscal year 2015 dividend payout ratio to appr... 
Download PDFPrinter Friendly Version
06/15/14Medtronic to Acquire Covidien for $42.9 billion in Cash and Stock
Creates a Medical Technology and Services Company with a Comprehensive Product Portfolio and Broad Global Reach that is Better Able to Improve Healthcare Outcomes Meaningfully Accelerates Medtronic's Core Strategies of Therapy Innovation, Globalization and Economic Value Combined Revenue of $27 Billion, including $3.7 Billion from Emerging Markets Transaction Expected to be Accretive to Medtronic Cash Earnings in FY2016 and Significantly Accretive thereafter Medtronic Commits to $10 Billio... 
Download PDFPrinter Friendly Version
06/14/14Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes
Initial Focus on Insulin-Device Combinations and Care Management Services PARIS, FRANCE, AND MINNEAPOLIS, MN - June 14, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and Medtronic, Inc. (NYSE: MDT) today announced that they have signed a memorandum of understanding to enter into a global strategic alliance in diabetes, aimed at improving patient experience and outcomes for people with diabetes around the world. The alliance will initially focus on two key priorities: the development of drug-devic... 
 Printer Friendly Version
06/12/14Medtronic CoreValve® System Receives FDA Approval for Patients at High Risk for Surgery
Accelerated Approval Obtained after Clinical Outcomes with Self-Expanding Valve Prove Superior to Surgical Aortic Valve Replacement at One Year CoreValve System Now Available to More U.S. Patients than any Other Transcatheter Aortic Valve MINNEAPOLIS - June 12, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the self-expanding transcatheter CoreValve® System for patients with severe aortic stenosis who are at high risk for surgery.This... 
Download PDFPrinter Friendly Version
06/11/14Medtronic Announces Date for 2014 Annual Meeting
Shareholders Invited to Attend Annual Meeting on Aug. 21, 2014 MINNEAPOLIS - June 11, 2014 - The board of directors of Medtronic, Inc. (NYSE: MDT), announced that the company's annual meeting of shareholders will be held at 10:30 a.m. CDT on Thursday, Aug. 21, 2014 at Medtronic's Mounds View campus, located at 8200 Coral Sea Street N.E., Mounds View, Minnesota.  Shareholders of record at the close of business on June 23, 2014, will be eligible to vote at the meeting. About MedtronicMedtronic, ... 
 Printer Friendly Version
06/11/14Medtronic Submits Final Data to FDA for Novel Device to Treat Peripheral Artery Disease
Global Leader Projects Introduction of IN.PACT Admiral Drug-coated Balloon to U.S. Market in Early FY16 MINNEAPOLIS - Date - Moving toward U.S. market introduction of its novel medical device to treat peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced that it recently submitted the final module of its pre-market approval (PMA) application for the IN.PACT Admiral drug-coated balloon to the U.S. Food and Drug Administration (FDA). The application includes data that demonstra... 
Download PDFPrinter Friendly Version
06/10/14Medtronic CFO Gary Ellis to Speak at Wells Fargo Healthcare Conference
MINNEAPOLIS - June 10, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Wells Fargo Healthcare Conference on Tuesday, June 17, 2014, in Boston. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 2:20 p.m. EDT (1:20 p.m. CDT). A live audio webcast of the presentation will be available on June 17, 2014, by clicking on the Investors link... 
Download PDFPrinter Friendly Version
06/05/14Medtronic Outlines Future Growth Opportunities at Investor Conference
MINNEAPOLIS -- Jun. 5, 2014 -- Medtronic, Inc. (NYSE: MDT) shared during its Investor Conference today in New York City an overview of the state of its business and strategies for future growth opportunities. Chairman and CEO Omar Ishrak emphasized the opportunity that exists to address universal healthcare needs: improving clinical outcomes, expanding access, and optimizing cost and efficiency.  He also emphasized the company's integrated health solutions offerings and focus on improving operat... 
Download PDFPrinter Friendly Version
06/04/14Medtronic Expands Availability of Market-Leading Aortic & Peripheral Solutions to U.S. Market
Recently FDA Approved Valiant Captivia Proximal FreeFlo Tapers for Dissection and TOTAL Across Crossing Support Catheter Featured at the 2014 Vascular Annual Meeting MINNEAPOLIS -- Jun. 4, 2014 -- Continuing to expand its market-leading portfolio of endovascular solutions, Medtronic, Inc. (NYSE: MDT) announced today that two recently Food and Drug Administration (FDA) approved devices will be featured at the Society for Vascular Surgery's 2014 Vascular Annual Meeting, taking place June 5-7 in B... 
Download PDFPrinter Friendly Version
06/03/14Medtronic CEO Omar Ishrak to Speak at Goldman Sachs Global Conference
MINNEAPOLIS - June 3, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 35th annual Goldman Sachs Global Healthcare Conference on Tuesday, June 10, 2014, in Rancho Palos Verdes, CA. Omar Ishrak, chairman and chief executive officer of Medtronic will make a presentation about Medtronic beginning at 3:20 p.m. PDT (5:20 p.m. CDT). A live audio webcast of the presentation will be available on June 10, 2014, by clicking o... 
Download PDFPrinter Friendly Version
06/03/14Medtronic Begins Initial European Market Launch of World's First Combined Glucose Sensor and Insulin Infusion Set for People with Diabetes
MiniMed® Duo(TM) Enhances Simplicity and Comfort of Sensor Augmented Insulin Pump Therapy  TOLOCHENAZ, SWITZERLAND - June 3, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the European launch of MiniMed® Duo(TM), the world's first two-in-one breakthrough that combines a glucose sensor and insulin infusion set into one on-body device, simplifying integrated insulin pump therapy and continuous glucose monitoring (CGM). MiniMed Duo, which is used with the MiniMed® Veo(TM) system, makes it easie... 
Download PDFPrinter Friendly Version
06/02/14Medtronic Opens Applications for 2014 Bakken Invitation Award; Unveils Online Community to Connect People With Medical Devices Who "Live On. Give On."
(View Bakken Invitation Video (PSA) Here) Medtronic Will Donate $10 to Project HOPE for Every Story Shared Online MINNEAPOLIS - June 2, 2014- Medtronic, Inc. (NYSE: MDT) today opened 2014 award applications for the Bakken Invitation, a global program designed to celebrate and connect people who, with the help of medical technology, have overcome health challenges and are now selflessly giving back to their communities. In its second year, the Bakken Invitation Award honors ten inspirational... 
Download PDFPrinter Friendly Version
06/02/14Medtronic Launches Advisa and Ensura SR MRI(TM) SureScan® Pacemaker Systems in Europe
Single-chamber Devices Receive CE Mark for Full Body MRI Scans Without Positioning Restrictions MINNEAPOLIS - June 2, 2014 - Medtronic, Inc. (NYSE: MDT), today announced CE (Conformité Européenne) Mark and commercial launch of the Advisa® and Ensura SR MRI(TM) SureScan® single chamber pacemaker devices in Europe. Both pacemakers are approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. These devices are not approved in the United States. MRI is the standard ... 
Download PDFPrinter Friendly Version
05/21/14Medtronic CoreValve® System Demonstrates Positive Clinical Performance at Two Years in 'Real World' ADVANCE Study
Rigorous Two-Year Analyses Presented at EuroPCR 2014 Affirm Safety, Efficacy and Sustained Valve Performance of Self-Expanding Valve PARIS and MINNEAPOLIS - May 21, 2014 - Medtronic, Inc. (NYSE: MDT) today revealed new data showing that patients treated with the CoreValve® System experienced positive clinical outcomes in the rigorous "real world" Medtronic CoreValve ADVANCE Study. Presented at EuroPCR 2014, the transcatheter aortic valve implantation (TAVI) study revealed low rates o... 
Download PDFPrinter Friendly Version
05/20/14Medtronic Announces CE Mark and Launch of NC Euphora(TM) Coronary Balloon
Noncompliant Balloon Provides Superior Deliverability and Controlled Growth for Challenging Coronary Angioplasty Procedures MINNEAPOLIS -- May 20, 2014 -- Continuing its commitment to bringing advanced and clinically relevant interventional technologies to market, Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européene) mark and launch of the NC Euphora(TM) Noncompliant Balloon Dilatation Catheter. The NC Euphora Balloon Catheter is now available in Europe and other countries outsi... 
Download PDFPrinter Friendly Version
05/20/14Medtronic Reports Fourth Quarter and Fiscal Year 2014 Earnings
Q4 Revenue of $4.6 Billion Grew 3% at Constant Currency; 2% as Reported Q4 Non-GAAP Diluted EPS of $1.12; GAAP Diluted EPS of $0.44 FY14 Revenue of $17.0 Billion Grew 4% at Constant Currency; 3% as Reported FY14 Free Cash Flow of $4.6 Billion; GAAP Cash Flow from Operations of $5.0 Billion Company Sets Initial FY15 Revenue Growth Outlook and EPS Guidance MINNEAPOLIS - May 20, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2... 
Download PDFPrinter Friendly Version
05/20/14Medtronic Settles Global Patent Litigation with Edwards Lifesciences
TAVI and Surgical Patent Cases Resolved MINNEAPOLIS - May 20, 2014 - Medtronic, Inc. (NYSE: MDT) announced that it has reached a global patent settlement agreement with Edwards Lifesciences Corporation (NYSE:EW). Under the terms of the cross-license settlement agreement, the parties will dismiss all of the pending litigation matters and patent office actions between them, and grant each other broad releases to  patent litigation claims. Medtronic will pay Edwards a one-time payment of $750 mi... 
Download PDFPrinter Friendly Version
05/19/14Medtronic Appoints Brad Lerman to Serve as Senior Vice President, General Counsel and Corporate Secretary
MINNEAPOLIS - May 19, 2014 - Medtronic, Inc. (NYSE: MDT) announced the appointment of Brad Lerman as senior vice president, general counsel and corporate secretary effective May 27, 2014. In this role, Lerman will report to Medtronic Chairman and CEO, Omar Ishrak. As senior vice president, general counsel and corporate secretary, Lerman will lead the global legal function across the company. In addition, he will direct Medtronic's government affairs department and serve as a member of Medtronic... 
 Printer Friendly Version
05/19/14Medtronic Applauds AACE/ACE on Their Updated Insulin Pump Therapy Consensus Statement
MINNEAPOLIS - May 19, 2014 - Medtronic, Inc. (NYSE:MDT) applauds the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) on their updated consensus statement on insulin pump therapy. In addition to continued support of insulin pump therapy for people with type 1 diabetes, AACE and ACE recognize the clinical value of insulin pumps in improving glucose control for those with intensively managed insulin-dependent type 2 diabetes. Improving glucos... 
Download PDFPrinter Friendly Version
05/14/14Arizona Manufacturers Council Names Medtronic's Tempe Campus 2014 Manufacturer of the Year
TEMPE, ARIZ. - May 14, 2014 - The Medtronic Tempe Campus, a manufacturing site for the world's leading medical technology company, has been named 2014 Manufacturer of the Year by the Arizona Manufacturers Council. The campus, located on a 30-acre site southeast of Phoenix Sky Harbor International Airport, is home to a world-class microelectronics manufacturing facility and technology center. "For this prestigious award, we select a manufacturer that produces superior products, provides hi... 
Download PDFPrinter Friendly Version
05/13/14Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2014
MINNEAPOLIS - May 13, 2014 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2014 on Tuesday, May 20, 2014. A news release will be issued at approximately 6:15 a.m. Central Daylight Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic's fourth quarter and fiscal year, which ended April 25, 2014. Medtronic will host a webcast at 7 a.m. Cen... 
Download PDFPrinter Friendly Version
05/13/14Medtronic Names Hooman Hakami Executive Vice President and Group President of the Medtronic Diabetes Group
MINNEAPOLIS - May 13, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the selection of Hooman Hakami as executive vice president and group president of the Medtronic Diabetes Group, the global leader in insulin pumps and continuous glucose monitoring systems.  In this role, Hakami will lead Medtronic's entire global diabetes franchise, including research and development, operations, and sales and marketing. Hakami previously served as president and CEO of GE Healthcare's Detection and Guidan... 
Download PDFPrinter Friendly Version
05/10/14Late-Breaking Clinical Trial Results Show Medtronic-Exclusive Pacemaker Algorithm Significantly Delays Atrial Fibrillation
MINERVA Trial Presented at Heart Rhythm Meeting Shows Medtronic Advanced Pacing Features Reduce the Progression of Persistent AF by 58 Percent While Reducing AF-Related Hospital Visits That Lead to Increased Healthcare Costs MINNEAPOLIS and SAN FRANCISCO - May 10, 2014 - New data presented as a late-breaking clinical trial at the Heart Rhythm Society's 2014 Annual Scientific Sessions show that an advanced pacing feature exclusive to Medtronic, Inc. (NYSE: MDT) pacemakers significantly delays t... 
Download PDFPrinter Friendly Version
05/10/14New Data Show That Defibrillators Programmed to Wait Longer to Deliver Therapy Are Safe for Secondary Prevention ICD Patients with Medtronic SmartShock Technology
Late-breaking Clinical Trial Data Confirm Industry Leadership with 1 Percent Inappropriate Shocks Using Medtronic SmartShock Technology MINNEAPOLIS and SAN FRANCISCO - May 10, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the results from the first prospective randomized clinical trial to show that Medtronic implantable cardioverter defibrillators (ICDs) can safely extend detection times before triggering therapy in secondary prevention patients. The results of the PainFree SST sub-study, ... 
Download PDFPrinter Friendly Version
05/09/14Medtronic Announces 2014 Analyst Meeting and Webcast
MINNEAPOLIS - May  9, 2014 - Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Thursday, June 5, 2014, in New York City from 8:30 a.m. to approximately 1:00 p.m. Eastern Daylight Time.  The meeting will include remarks from the Medtronic management team highlighting the company's strategy for executing on its growth vectors to expand its market leadership position, delivering consistent and reliable performance, and creating long-term shareholder value. Medtronic... 
Download PDFPrinter Friendly Version
05/09/14Study Shows Promising Results with Novel Approach to Medtronic Cardiac Resynchronization Therapy
Late-Breaking Clinical Trial Data Show Implant Success with Pacing Inside the Left Ventricle in Heart Failure Patients MINNEAPOLIS and SAN FRANCISCO - May 9, 2014 - Medtronic, Inc. (NYSE: MDT) today released study findings that show heart failure patients who have limited options for implanted device therapy may benefit from a novel implant technique for cardiac resynchronization therapy (CRT) devices. Data from the ALSYNC (Alternate Site Cardiac Resynchronization) study show that pacing from ... 
Download PDFPrinter Friendly Version
05/06/14Medtronic Agrees to Settle Certain INFUSE® Bone Graft Product Liability Cases
MINNEAPOLIS - MAY 6, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has agreed with certain plaintiffs' counsel to settle their inventories of filed and unfiled product liability claims related to INFUSE® Bone Graft.  Under the terms of the agreement, Medtronic has agreed, subject to certain conditions, to resolve the claims of an estimated 950 claimants for a total payment of approximately $22 million.  This agreement is a compromise of disputed claims and is not in any way an adm... 
 Printer Friendly Version
05/01/14Ten Local High School Graduates Named 2014 Medtronic Wallin Scholars
Medtronic has committed more than $1.7 million in local scholarships to 110 students. MINNEAPOLIS - May 1, 2014 - Medtronic today announced that 10 students have been selected as 2014 Medtronic Wallin Scholars. Each will receive a four-year scholarship totaling $16,000, as well as support services to assist them in their collegiate studies. Students represent nine Twin Cities' north suburban high schools, and one Minneapolis high school. The class of 2014 Medtronic Wallin Scholars will be honor... 
 Printer Friendly Version
05/01/14Medtronic Viva® Cardiac Resynchronization Therapy-Pacemaker Now Available in Europe
New Device Automatically Adapts to Patient Needs, Continuously Optimizes Therapy,Improves Response Rate and Reduces Heart Failure Hospitalizations MINNEAPOLIS, MAY 1, 2014 - Medtronic, Inc. (NYSE:MDT) today announced CE (Conformité Européenne) Mark receipt and the European launch of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P. The Viva CRT-P is not approved for sale in the United States. The Viva CRT-P includes the Medtronic-exclusive AdaptivCRT® software, which is the... 
Download PDFPrinter Friendly Version
04/29/14Medtronic Reveals Positive Outcomes for CoreValve® Patients Treated via Alternative Access Routes
AATS Late-Breaker Data Show Strong Clinical Results in Complex Patient Population                                                                                                   TORONTO and MINNEAPOLIS - April 29, 2014 - Medtronic, Inc. (NYSE: MDT) today revealed new data demonstrating positive outcomes for extreme risk patients with severe aortic stenosis who were treated with the CoreValve® System via alternative access approaches. The compelling data were unveiled during a late-breakin... 
Download PDFPrinter Friendly Version
04/29/14Medtronic Sutureless Heart Valve First to Show Five-Year Safety and Efficacy Outcomes
Less-Invasive Surgical Aortic Valve Demonstrates Sustained Durability MINNEAPOLIS - April 29, 2014 -Medtronic, Inc. (NYSE: MDT) today announced five-year follow-up data demonstrating the safety and performance of the Medtronic 3f Enable® Aortic Bioprosthesis - the world's first commercially available sutureless tissue heart valve.  The longest follow-up data ever reported for a sutureless bioprosthesis, results showed that patients implanted with 3f Enable displayed no structural valve deterio... 
Download PDFPrinter Friendly Version
04/28/14Medtronic Among Top U.S. Corporate Citizens, According to Corporate Responsibility Magazine
MINNEAPOLIS - April 28, 2014 - Medtronic has been recognized as a top U.S. corporate citizen by Corporate Responsibility Magazine. The publication's 100 Best Corporate Citizens List, released this week, recognizes companies for their commitment to the environment, climate change, employee relations, human rights, governance, finance and philanthropy. Corporate Responsibility magazine's rating is based on publicly available information and is recognized as one of the nation's top measurements o... 
 Printer Friendly Version
04/22/14Medtronic Announces First U.S. Implant of Implantable Cardioverter-Defibrillator System Designed to Allow Full-Body MRI Scans
First Patient Enrolled in U.S. Pivotal Clinical Trial to Evaluate the Evera MRI(TM) ICD System MINNEAPOLIS - April 22, 2014 -Medtronic today announced the first U.S. implant of the Evera MRI(TM) SureScan® implantable cardioverter-defibrillator (ICD) System, following U.S. Food and Drug Administration (FDA) approval for its Investigational Device Exemption (IDE) application and pivotal clinical trial protocol. Evera MRI is the first ICD system to be evaluated in the U.S. that allows for magnetic... 
Download PDFPrinter Friendly Version
04/21/14Federal Appeals Court Agrees to Medtronic Request to Postpone Injunction
MINNEAPOLIS - April 21, 2014 - The Federal Circuit Court of Appeals today granted a request from Medtronic, Inc. (NYSE: MDT) to postpone the implementation of an  injunction that would have prevented the company from selling its CoreValve® System in the United States. This means the injunction will only take effect if the appellate court determines the injunction was properly issued. In addition, last week the Court of Appeals agreed to an expedited appeal of the injunction ruling, with the las... 
Download PDFPrinter Friendly Version
04/21/14Update on CoreValve Federal District Court Ruling; Court Agrees to Expedited Appeal
MINNEAPOLIS - April 21, 2014 - Medtronic, Inc. (NYSE: MDT) today issued an updated statement on the recent ruling by Federal District Court of Delaware. The ruling granted in part Edwards Lifesciences' motion for a preliminary injunction that prevents Medtronic from selling or offering to sell its CoreValve® System in the United States, except through a mechanism that Medtronic is pursuing with Edwards Lifesciences that would allow currently trained sites to treat patients with CoreValve based o... 
Download PDFPrinter Friendly Version
04/18/14Endurant AAA Stent Graft from Medtronic Continues Exceptional Long-Term Performance in Observational Studies
New Clinical Data from PANDORA and ENGAGE Affirm Market-Leading Medical Device's Durable, Consistent and Proven Outcomes In Endovascular Treatment of Abdominal Aortic Aneurysms MINNEAPOLIS -- April 18, 2014 -- The Endurant AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to demonstrate exceptional long-term performance in the endovascular treatment of abdominal aortic aneurysms, according to new clinical data presented for the first time at the 2014 Charing Cross international... 
Download PDFPrinter Friendly Version
04/11/14Medtronic to Appeal Federal District Court Ruling
MINNEAPOLIS - April 11, 2014 - The Federal District Court of Delaware today granted in part Edwards Lifesciences' motion for a preliminary injunction that prevents Medtronic, Inc. (NYSE: MDT) from selling or offering to sell its CoreValve® System in the United States. Today's ruling has no impact on the sale or marketing of CoreValve outside of the United States or the use of CoreValve in the current U.S. clinical trials. At Medtronic's request, the Federal District Court agreed to postpone the... 
Download PDFPrinter Friendly Version
04/10/14Medtronic CRT Devices Now Approved to Treat Patients with AV Block and Reduced Heart Function
Landmark BLOCK HF Trial Demonstrates Clinical Benefits of Biventricular Pacing in New Patient Population MINNEAPOLIS - April 10, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization therapy-pacemakers and -defibrillators (CRT-P and CRT-D). Medtronic CRT devices are now approved to treat patients with atrioventricular (AV) block and left ventricul... 
 Printer Friendly Version
04/09/14Medtronic Announces CE Mark and European Launch of First Implantable Cardioverter-Defibrillator System to Allow for Full-Body MRI Scans
Evera MRI(TM) ICD System Is First to Combine Proven Treatment Performance, Increased Longevity, Improved Comfort with Full-Body MRI Access MINNEAPOLIS - April 9, 2014 - Medtronic today announced CE (Conformité Européenne) Mark and European launch of the Evera MRI(TM) SureScan® implantable cardioverter-defibrillator (ICD) System, the first and only ICD system approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. The Medtronic Evera MRI ICD is not approved in t... 
Download PDFPrinter Friendly Version
04/07/14Medtronic Acquires Majority of the Shares of Biostar Creating a New Medtronic-Medicall Collaboration in Turkey
ISTANBUL - April 7, 2014 - Medtronic, Inc. today announced that one of its subsidiaries has acquired a majority of the shares of Biostar, which will assume the distribution of Medtronic products in Turkey formerly distributed by Medicall Biomedikal A.S., creating a new collaboration between Medtronic and Medicall in Turkey. The transaction is intended to support Medtronic's strategy to get even closer to the customer, improve and increase efforts in market development, and accelerate growth. T... 
Download PDFPrinter Friendly Version
04/05/14'IN.PACT Admiral' Drug-Coated Balloon From Medtronic Outperforms Standard Angioplasty In Landmark Study
Interventional Treatment of Lower-Extremity Peripheral Arterial DiseaseWith Novel Medical Device Shows Positive Results in IN.PACT SFA Trial LONDON -- April 5, 2014 --Patients with peripheral artery disease in the upper leg experienced significantly better outcomes at 12 months after treatment with the IN.PACT Admiral drug-coated balloon from Medtronic, Inc. (NYSE: MDT) than with standard balloon angioplasty, according to a landmark clinical study reported on today for the first time. The IN.P... 
Download PDFPrinter Friendly Version
03/31/14Medtronic CoreValve® System Demonstrates Long-Term Durability
Final Follow-up of CoreValve CE Pivotal Study Shows Sustained Valve Function  MINNEAPOLIS - March 31, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the final follow-up results from the CoreValve® CE Pivotal Study, which demonstrated excellent long-term durability at four years in patients with severe aortic stenosis who were treated with the self-expanding CoreValve System.  The results were presented for the first time at the 63rd Annual Scientific Session of the American College of Cardi... 
Download PDFPrinter Friendly Version
03/30/14Medtronic Global SYMPLICITY Registry Shows Strong Safety Profile of the Symplicity(TM) Renal Denervation System
Six-Month Analysis of First 1,000 Patients Enrolled in Real-World Patient Registry Presented at ACC.14 MINNEAPOLIS and WASHINGTON, D.C. - March 30, 2014 - Medtronic, Inc. (NYSE: MDT), announced today further analysis of six-month follow-up data from the first 1,000 patients enrolled in the Global SYMPLICITY Registry, which continue to demonstrate the safety of the Symplicity(TM) renal denervation system. Presented today during a late-breaking clinical trial session at the 63rd Scientific Sessio... 
Download PDFPrinter Friendly Version
03/30/14World's First Transcatheter Valve, Medtronic Melody® Transcatheter Pulmonary Valve Shows Positive Clinical Outcomes in Real-World Study
Has Repaired Hearts of 6,000+ Patients; More Than Half Are Children MINNEAPOLIS and WASHINGTON - March 30, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the one-year results of the Melody® Transcatheter Pulmonary Valve (TPV) U.S. Post-Approval Study, which found that real-world use of the Melody TPV was associated with high procedural success, excellent valve function and few repeat procedures at the primary endpoint of six months. These results were sustained out to one year. The Melod... 
Download PDFPrinter Friendly Version
03/29/14Medtronic CoreValve® System Results Superior to Open-Heart Surgery at One Year in U.S. Pivotal Trial
CoreValve High Risk Study: FDA Determines Expert Panel Not Required Low Mortality Rate Exceeds Expectations for Primary Endpoint CoreValve System is First and Only Transcatheter Aortic Valve to Show Results  Superior to Surgical Aortic Valve Replacement MINNEAPOLIS and WASHINGTON - March 29, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the CoreValve® System showed results superior to surgical aortic valve replacement (SAVR) at one year in the High Risk Study of its CoreValve U.... 
 Printer Friendly Version
03/29/14Medtronic Releases Results of SYMPLICITY HTN-3
Medtronic Commits to Further Clinical Investigation and Determining Path Forward for Next U.S. IDE with FDA MINNEAPOLIS and WASHINGTON, DC - March 29, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the full results of the SYMPLICITY HTN-3 clinical trial, which were presented today in late-breaking session at the 63rd Scientific Sessions of the American College of Cardiology (ACC) and published simultaneously in The New England Journal of Medicine. SYMPLICITY HTN-3, the first and only blind... 
Download PDFPrinter Friendly Version
03/27/14First Patients Enrolled in Medtronic Clinical Study Designed to Identify Patients at High Risk for Sudden Cardiac Arrest in Developing Countries
Study Will Assess Defibrillator Therapy in Patients Most At-Risk for SCA Minneapolis - March 27, 2014 -Medtronic, Inc. (NYSE:MDT) today announced the first patients were enrolled in the Improve SCA Clinical Study, a first-of-its-kind study that will identify patients in developing countries at a high risk for sudden cardiac arrest (SCA) - an abrupt loss of heart function that can lead to death in minutes - who have not previously experienced a life threatening arrhythmia (primary prevention p... 
Download PDFPrinter Friendly Version
03/10/14Medtronic Seeking Long-Distance Runners Who Benefit From Medical Technology
"Global Heroes" Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October MINNEAPOLIS - March 10, 2014 - Medtronic, Inc. (NYSE: MDT) announced today applications are open to runners around the world who benefit from medical technology to represent their country on the 2014 Medtronic Global Heroes team. Up to 25 runners will be selected to receive a paid entry for themselves and a guest to the Medtronic Twin Cities Marathon or the Medtronic TC ... 
 Printer Friendly Version
03/06/14Medtronic CFO Gary Ellis to Speak at Barclays Global Healthcare Conference
MINNEAPOLIS - Mar 6, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Barclays Global Healthcare Conference on Wednesday, March 12, 2014, in Miami. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 4:15 p.m. EDT (3:15 p.m. CDT). A live audio webcast of the presentation will be available on March 12, 2014, by clicking on the Investors lin... 
Download PDFPrinter Friendly Version
03/06/14Medtronic Wins European Patent Office Ruling
MINNEAPOLIS - March 6, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the European Patent Office (EPO) has invalidated, in its entirety, the Edwards Lifesciences EP2055266 Spenser patent which was the basis for the Aug. 26, 2013  injunction prohibiting sales of the CoreValve® System in Germany. In its ruling, the EPO in The Hague said the entire patent is invalid and therefore revoked. "Medtronic is very pleased with this ruling as it will ensure that patients across Europe who n... 
Download PDFPrinter Friendly Version
03/03/14Aetna and Medtronic Collaborate to Help Members Take Better Control of Type 2 Diabetes
- Program Aims to Improve Patients' Quality of Life and Enhance Support for Doctors to Help Create More Value in the Health Care System - HARTFORD, Conn. and MINNEAPOLIS, March 3, 2014 - Beginning this month, Aetna (NYSE: AET) and Medtronic, Inc. (NYSE: MDT) will work with doctors in a new program to reach up to 300 fully insured members with uncontrolled type 2 diabetes who may improve their health using insulin pump therapy. Eligible members will receive targeted education, case management a... 
 Printer Friendly Version
02/27/14Medtronic EVP & President Mike Coyle to Speak at Cowen Healthcare Conference
MINNEAPOLIS - Feb 27, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014, in Boston. Mike Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group, will make a presentation about Medtronic beginning at 11:20 a.m. EST (10:20 a.m. CST). A live audio webcast of the presentation will be available on March 5, 2014... 
Download PDFPrinter Friendly Version
02/21/14Medtronic Announces Public Offering of Senior Notes
MINNEAPOLIS -- February 21, 2014 -- On February 20, 2014, Medtronic, Inc. (NYSE: MDT) registered an offering of $250 million principal amount of its 0.875% Senior Notes due 2017, $250 million principal amount of its floating rate Senior Notes due 2017, $850 million principal amount of its 3.625% Senior Notes due 2024, and $650 million principal amount of its 4.625% Senior Notes due 2044 (collectively, the "Notes").  The closing of the offering is expected to occur on February 27, 2014,... 
Download PDFPrinter Friendly Version
02/20/14Medtronic Announces First U.S. Implant of World's Smallest, Minimally Invasive Cardiac Pacemaker
Medtronic Enrolls First U.S. Patient in Global Clinical Trial for Miniature Transcatheter Pacemaker System MINNEAPOLIS - Feb. 20, 2014 - Continuing its leadership in advanced pacing technology and device miniaturization, Medtronic, Inc. (NYSE: MDT), today announced the first U.S. implant of the world's smallest pacemaker: the Micra(TM) Transcatheter Pacing System (TPS). The device was successfully implanted at NYU Langone Medical Center by Larry Chinitz, M.D., director of the Heart Rhythm Cente... 
Download PDFPrinter Friendly Version
02/19/14Medtronic Announces Global Launch of Miniature Cardiac Monitor, Reveal LINQ(TM) ICM
Small, Wireless Monitor Provides Long-Term Remote Monitoring to Help Physicians Diagnose and Monitor Irregular Heartbeats MINNEAPOLIS - February 19, 2014 -Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance, CE (Conformité Européenne) Mark, and the global launch of its Reveal LINQ Insertable Cardiac Monitor (ICM) System, the smallest implantable cardiac monitoring device available for patients.   The Reveal LINQ ICM is approximately one-third t... 
Download PDFPrinter Friendly Version
02/18/14Medtronic EVP & President Chris O'Connell to Speak at Citi Global Healthcare Conference
MINNEAPOLIS - Feb 18, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 2014 Citi Global Healthcare Conference on Monday, February 24, 2014, in New York City. Chris O'Connell, executive vice president and president of Medtronic's Restorative Therapy Group, will make a presentation about Medtronic beginning at 3:30 p.m. EST (2:30 p.m. CST). A live audio webcast of the presentation will be available on February 24, 201... 
Download PDFPrinter Friendly Version
02/18/14Medtronic Reports Third Quarter Earnings
Revenue of $4.2 Billion Grew 4% on a Constant Currency Basis; 3% as Reported Non-GAAP Diluted EPS of $0.91; GAAP Diluted EPS of $0.75 Free Cash Flow of $1.5 Billion; GAAP Cash Flow from Operations of $1.6 Billion Reiterates FY14 Revenue Outlook; Tightens FY14 Diluted EPS Guidance MINNEAPOLIS - Feb. 18, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2014, which ended January 24, 2014. The company reported worldwide third quarter ... 
Download PDFPrinter Friendly Version
02/14/14Study Finds Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation In Stroke Patients Better Than Standard Care
MINNEAPOLIS - February 14, 2014 - Medtronic, Inc. (NYSE: MDT), today announced results from the CRYSTAL AF (CRYptogenic STroke And underLying Atrial Fibrillation) Clinical Trial, which found that continuous cardiac monitoring with the Reveal® XT Insertable Cardiac Monitor (ICM) was superior to standard care at detecting atrial fibrillation (AF) in patients who have had strokes of undetermined causes (cryptogenic stroke). Presented at a late-breaking science session at the American Stroke Associa... 
Download PDFPrinter Friendly Version
02/13/14Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2014
MINNEAPOLIS - February 13, 2014 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.28 per share of the Company's common stock. The quarterly dividend represents an 8% increase over the prior year. The dividend is payable on April 25, 2014, to shareholders of record at the close of business on April 4, 2014. Medtronic, a constituent of the S&P 500 Dividend Aristocrat index, remains committed to returning 50% percent of its free cash flow to shareholders th... 
Download PDFPrinter Friendly Version
02/13/14Medtronic Begins Distribution of i-port Advance® Injection Port Device for People with Diabetes
Distribution Rights Broaden Medtronic's Diabetes Management Solutions to Include Injection Therapy Assistance MINNEAPOLIS - February 13, 2014 - Medtronic, Inc. (NYSE:MDT) has begun distribution of i-port Advance® as part of a continued focus to provide meaningful therapy management solutions for people with diabetes. i-port Advance can be used for people on insulin injection therapy who want to administer insulin conveniently while eliminating the need to puncture the skin with each dose of med... 
Download PDFPrinter Friendly Version
02/13/14Medtronic Launches 'TOTAL Across' Crossing Catheter in Europe
New Peripheral Device Targets Challenging Lesions in Lower-Extremity, Including Below-the-Knee, Arteries Associated with Critical Limb Ischemia MINNEAPOLIS -- Feb. 13, 2014 -- Aligned with its commitment to provide innovative medical technology for the interventional treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) has initiated the European launch of the TOTAL across crossing catheter, which recently received the CE (Conformité Européene) mark as a tool for improving bl... 
Download PDFPrinter Friendly Version
02/11/14Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2014
MINNEAPOLIS - Feb. 11, 2014 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2014 on Tuesday, February 18, 2014. A news release will be issued at approximately 6:15 a.m. CST and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic's third quarter, which ended January 24, 2014. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial ... 
Download PDFPrinter Friendly Version
01/28/14Valiant Captivia Thoracic Stent Graft System From Medtronic Receives FDA Approval for Treating Aortic Dissections
Supported by Recently Presented Study Results, New Indication Expands Treatment Options for Patients with Dangerous Tear in Upper Segment of Body's Main Artery MINNEAPOLIS -- Jan. 28, 2014 -- Continuing to expand the role of endovascular aortic repair, Medtronic, Inc. (NYSE: MDT) has received approval from the U.S. Food and Drug Administration (FDA) for the Valiant Captivia Thoracic Stent Graft System to be used in the treatment of type B aortic dissections, a serious cardiovascular condition a... 
Download PDFPrinter Friendly Version
01/28/14Medtronic Relocates Its Regional Headquarters to Dubai
Committed to Healthcare Education with its Leading Medical Technology Innovations Dubai, UAE - 28 January 2014, Medtronic, Inc. (NYSE: MDT), the world's largest medical technology company, providing therapies to treat many conditions including cardiac and vascular diseases, diabetes, neurological and spinal conditions, today announced the relocation of its regional Middle East and Africa (MEA) headquarters to Dubai. The company will relocate all its regional operations to TECOM Investment's ... 
 Printer Friendly Version
01/22/14Medtronic Statement on U.S. Supreme Court Ruling in Medtronic, Inc. v. Mirowski Family Ventures
MINNEAPOLIS - Jan. 22, 2014 - Medtronic, Inc. (NYSE: MDT) announced that the U.S. Supreme Court ruled 9-0 in favor of Medtronic that the burden of proving infringement rests with the party asserting a product infringes, even if a license exists between the patent holder and product manufacturer.  The ruling came in the case of Medtronic, Inc. v. Mirowski Family Ventures."We are very pleased with the Court's unanimous ruling, which affirmed in this case there is no reason burden of proof law... 
 Printer Friendly Version
01/22/14Medtronic SureScan® Pacing Systems First to Be Approved for Full Body MRI Scans Without Positioning Restrictions
Data Verifies Safety of MRI Scans for Any Region of the Body in Patients with Medtronic SureScan®Pacing Systems MINNEAPOLIS - January 22, 2014 - Medtronic, Inc. (NYSE: MDT), today announced that the Medtronic SureScan® pacing systems - the first and only pacing systems in the United States that have been approved by the U.S. Food and Drug Administration (FDA) for use with magnetic resonance imaging (MRI) - are now approved for MRI scans positioned on any region of the body. Patients implanted w... 
Download PDFPrinter Friendly Version
01/17/14Medtronic CoreValve® System Obtains Early FDA Approval on Exceptional Clinical Performance
Self-Expanding Aortic Valve Serves Broad Spectrum of Potential Transcatheter Aortic Valve Replacement (TAVR) Patients Who Are Unable to Undergo Surgery MINNEAPOLIS - Jan. 17, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the self-expanding transcatheter CoreValve® System for severe aortic stenosis patients who are too ill or frail to have their aortic valves replaced through traditional open-heart surgery. Untreated, these patients ha... 
Download PDFPrinter Friendly Version
01/15/14Medtronic to Appeal Federal District Court Verdict
MINNEAPOLIS - Jan. 15, 2014 - A jury in the Federal District Court of Delaware today decided in favor of Edwards Lifesciences, ruling that the Medtronic (NYSE:MDT) CoreValve® System infringed on Edward's Cribier patent (US Pat. No. 8,002,825). Medtronic intends to appeal. "While we are disappointed in the jury's verdict, we continue to believe that this decision will be overturned on appeal," said Neil Ayotte, vice president and acting general counsel at Medtronic. "Medtronic has... 
Download PDFPrinter Friendly Version
01/09/14Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint
MINNEAPOLIS - January 9, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and the trial's Data Safety Monitoring Board (DSMB) concluded that there were no safety concerns in the study. "SYMPLICITY HTN-3 met its primary safety endpoint related to the incidence of major adverse events one month fol... 
Download PDFPrinter Friendly Version
01/06/14Medtronic Announces Acquisition of TYRX, INC., Developer of Solutions for Surgical Site Infections
MINNEAPOLIS - Jan. 06, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has acquired TYRX, Inc., a privately held, New Jersey-based developer of implantable combination antibiotic drug and implanted medical devices.  TYRX's product offerings include the recently FDA cleared AIGISRx® R Fully Resorbable Antibacterial Envelope, designed to reduce surgical site infections associated with Cardiac Implantable Electronic Devices (CIEDs), and the AIGISRx® N Antibacterial Envelope, for use with... 
Download PDFPrinter Friendly Version
01/06/14Medtronic Begins VICTORY AF Trial of Patients with Persistent or Long-Standing Persistent Atrial Fibrillation
MINNEAPOLIS - Jan. 6, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the first patient has been enrolled in the VICTORY AF clinical trial, a prospective, non-randomized, controlled study of patients with persistent or long-standing persistent atrial fibrillation (AF) undergoing an ablation procedure with Medtronic's Phased Radiofrequency (RF) system. The study will evaluate the safety of this system, while collecting additional effectiveness data. The Medtronic Phased RF System is investigati... 
Download PDFPrinter Friendly Version
01/06/14Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference
MINNEAPOLIS - Jan 6, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 32nd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014, in San Francisco. Omar Ishrak, chairman and chief executive officer of Medtronic will make a presentation about Medtronic beginning at 9:30 a.m. PST (11:30 a.m. CST). A live audio webcast of the presentation will be available on January 13, 2014, by clicking on the Investor... 
Download PDFPrinter Friendly Version


Section Navigation

Spotlight

Medtronic to acquire Covidien. Learn More.

Media contact:
Fernando Vivanco
fernando.vivanco
@medtronic.com

763-505-3780

Contact Us

Medtronic
Medtronic, Inc.
main number(763) 514-4000
Medtronic
Public Relations
710 Medtronic Pkwy NE LC-110
Minneapolis, MN  55432

Media Contacts

Latest Tweets

Medtronic News
@Medtronic

Latest Tweets

Omar Ishrak
@MedtronicCEO